Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04514419 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Nov 20, 2021 to Sep 11, 2024v2 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Nov 20, 2021 to Dec 2025
    • Start date: Jun 30, 2020 to Jun 28, 2020
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).
Trial Details
NCT Number NCT04514419
Lead Sponsor BioRay Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 408 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov